China Shineway Pharmaceutical Group Limited (Shineway) has released its tenth Environmental, Social and Governance (ESG) Report, detailing performance for the year ended 31 December 2025. Key findings are summarised below.
Environmental Performance • Greenhouse-gas (GHG) profile: Total emissions (Scope 1, 2 and 3) reached 92,299.80 tCO₂e, 3.04% lower than 2024, yet GHG intensity (Scope 1 & 2) rose 20.12% to 23.79 tCO₂e per million RMB sales as longer operation of coal-fired boilers outweighed sales declines. • Energy use: Total energy consumption climbed 22.73% to 72.44 MWh per million RMB sales, reflecting higher coal usage; electricity demand fell 7.01% to 26.67 million kWh. • Water stewardship: Water withdrawal totalled 280,444 tonnes, with intensity up 15.80% to 89.44 tonnes per million RMB sales. A 5,000-tonne/day treatment plant and circulating-water reuse projects supported 80% recirculation rates. • Waste management: Non-hazardous waste intensity declined 1.63% to 3.73 tonnes per million RMB sales; hazardous waste remained de-minimis at 2.35 tonnes. Shineway targets a 2% reduction in waste and resource intensities by 2030 (baseline 2025). • Certifications: All production sites hold ISO 14001; Hebei authorities selected the facility as a provincial “Green Factory”.
Climate Strategy and Targets • Governance: Board-level Corporate Social Responsibility and Sustainability Committee oversees climate risks; all directors received sustainability training. • Transition roadmap: Short-, medium- and long-term goals call for successive 2%, 5% and 10% cuts in GHG, energy, water and non-hazardous waste intensities versus 2025. • Adaptation measures include fuel switching to biomass, ventilation upgrades, and supplier collaboration on low-carbon processes.
Social Metrics • Workforce: Headcount stood at 2,822 (52% women). Turnover was 20.82%; female representation in middle and senior management reached 21.57%. • Safety: Seven recordable injuries occurred; no fatalities. Lost-time injury rate was 0.38 per 200,000 hours. • Training: Shineway invested RMB0.78 million in staff development, delivering 3,080 training hours (1.05 hours per employee). • Community: Philanthropic spending totalled RMB4.78 million, of which RMB4.37 million supported relief for the Tai Po fire in Hong Kong. Employees contributed 846 volunteer hours.
Governance Highlights • Board composition: seven directors, 42.86% independent, 28.57% female. Independent directors chair the Audit and Remuneration Committees; all committees recorded 100% attendance. • No environmental fines, customer complaints, or corruption cases were reported in 2025.
Innovation and Product Quality • R&D spend reached RMB103.10 million. Shineway secured approvals for three additional classical Chinese medicine granule formulas, raising authorised invention patents to 197. No product recalls occurred.
Outlook Shineway reiterates its commitment to align with United Nations Sustainable Development Goals and Paris-aligned decarbonisation pathways, aiming for measurable intensity reductions across emissions, energy, water and waste while sustaining research‐driven growth in modern Chinese medicine.